



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,042	02/06/2006	Inger Mattsby-Baltzer	SYNE-S2400.2	5887
24184	7590	02/21/2008	EXAMINER	
LYNN E BARBER			TONGUE, LAKIA J	
P O BOX 16528			ART UNIT	PAPER NUMBER
FORT WORTH, TX 76162			1645	
MAIL DATE		DELIVERY MODE		
02/21/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/532,042	MATTSBY-BALTZER ET AL.
	Examiner	Art Unit
	Lakia J. Tongue	1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 21 April 2005.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-28 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) _____ is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) 1-28 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, drawn to a method for the diagnosis of candidiasis or invasive candidiasis comprising assaying with a combination of an IgG2 antibody to a phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*, and an IgG1 antibody to a *C. albicans* cell wall antigen, and glucan.

Group II, claim(s) 2-5, drawn to a method for the diagnosis of candidiasis or invasive candidiasis comprising assaying with an antibody to a *C. albicans* cell wall antigen.

Group III, claim(s) 2-5, drawn to a method for the diagnosis of candidiasis or invasive candidiasis comprising assaying with an antibody to a solubilized phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*.

Group IV, claim(s) 6 and 7, drawn to a kit for the diagnosis of candidiasis or invasive candidiasis comprising means for drawing a sample from a patient; means for an assay for the detection of a combination of an IgG2 antibody to a phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*, and an IgG1 antibody to a *C. albicans* cell wall antigen, and glucan, wherein said sample is analyzed for the presence of the simultaneous presence of an IgG2 antibody to a phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*, and an IgG1 antibody to a *C. albicans* cell wall antigen, and glucan.

Group V, claim(s) 8-12 and 24-26, drawn to a diagnostic kit for the diagnosis of candidiasis or invasive candidiasis comprising means for drawing a sample from a patient; means for an assay for the detection of an antibody to a *C. albicans* cell wall antigen or to a solubilized phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*, wherein said sample is analyzed for the presence of an antibody to a *C. albicans* cell wall antigen or to a solubilized phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*.

Group VI, claim(s) 13, drawn to a method for diagnosing candidiasis or invasive candidiasis in a patient comprising drawing a sample from the patient, and performing an assay for the detection of an IgG2 antibody to a phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*, and an IgG1 antibody to a *C. albicans* cell wall antigen, and glucan, wherein the simultaneous presence of an IgG2 antibody to a phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*, and an IgG1 antibody to a *C. albicans* cell wall antigen, and glucan indicates candidiasis in the patient.

Group VII, claim(s) 14, drawn to a method for diagnosing candidiasis or invasive candidiasis in a patient comprising drawing a sample from the patient, and performing an assay for the detection of an antibody to a *C. albicans* cell wall antigen or to a solubilized phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*, wherein the presence of an antibody to a *C. albicans* cell wall antigen or to a solubilized phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans* indicates candidiasis in the patient.

Group VIII, claim(s) 15-18 and 27, drawn to a method for the diagnosis of candidemia or invasive Candida infection comprising assaying with an antibody.

Group IX, claim(s) 19-21 and 28, drawn to a diagnostic kit for the diagnosis of candidemia or invasive Candida infection comprising means for drawing a sample from a patient; means for an assay for the detection of an IgG antibody to a native cell wall fragment of *C. albicans* or an IgG antibody to a solubilized phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*, wherein said sample is analyzed for the presence of an IgG antibody to a native cell wall fragment of *C. albicans* or an IgG antibody to a solubilized phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*.

Group X, claim(s) 22 and 23, drawn to a method for diagnosing candidemia or invasive Candida infection in a patient comprising drawing a sample from the patient, and performing an assay for the detection of an IgG antibody to a native cell wall fragment of *C. albicans*, wherein the presence of an IgG antibody to a native cell wall fragment of *C. albicans* indicates candidemia in the patient.

Group XI, claim(s) 22 and 23, drawn to a method for diagnosing candidemia or invasive Candida infection in a patient comprising drawing a sample from the patient, and performing an assay for the detection of an IgG antibody to a solubilized phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans*, wherein the presence of an IgG antibody to a solubilized phosphopeptidomannan (PPM) fraction of the cell wall of *C. albicans* indicates invasive Candida infection in the patient.

The technical feature linking Groups I-XI appears to be a *C. albicans* antibody. However, Han et al. (Infection and Immunity, 2000; 68(3): 1649-1654) disclose monoclonal antibody B6.1, which is specific for *C. albicans* (see abstract).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by

a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C.' 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lakia J. Tongue whose telephone number is 571-272-2921. The examiner can normally be reached on Monday-Friday 8-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

LJT
1/23/08



ROBERT A. ZEMAN
PRIMARY EXAMINER